Kevin Kelly

Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

TRIA Beauty, Inc. provides light based therapeutic beauty devices. It offers TRIA Laser Hair Removal System for laser removal of hair and TRIA Skin Perfecting Blue Light for mild to moderate inflammatory acne with a proprietary cleanser and serum for overall complexion improvement. The company was founded in 2003 by Tobin C. Island, Robert E. Grove, Jonathon T. Pearson and Mark V. Weckwerth and is headquartered in Dublin, CA.

Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA.

NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY.

Vicept Therapeutics Inc. develops dermatologic therapeutic products. The firm develops topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin. The company was founded on July 1, 2009 by Neal Walker, Stewart D. Shanler, and Christopher V. Powala and is headquartered in Malvern, PA.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

Frazier Life Sciences Management LP (Frazier Life Sciences) is a private investment manager headquartered in Menlo Park, California. The firm was founded in 2021 as a newly spun off company from Frazier Management LLC. They are principally owned by Jamie Topper and Patrick Heron. Frazier Life Sciences provides discretionary investment management services to US private investment funds, Frazier Life Sciences Funds.